DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial

This publication has 26 references indexed in Scilit:

• Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
  JACC: Cardiovascular Interventions, 2013
• Coronary stents: historical development, current status and future directions
  British Medical Bulletin, 2013
• Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial
  The Lancet, 2011
• Coronary Stents
  JACC, 2010
• Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
  New England Journal of Medicine, 2010
• Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
  2010
• Stent Thrombosis in Sweden
  Circulation: Cardiovascular Interventions, 2009
• Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions
  Circulation: Cardiovascular Interventions, 2009
• EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions
  EuroIntervention, 2008
• Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
  New England Journal of Medicine, 2003